Vaxcyte, Inc. (NASDAQ:PCVX) is Acuta Capital Partners LLC’s Largest Position

Acuta Capital Partners LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 22.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,400 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Vaxcyte comprises about 12.5% of Acuta Capital Partners LLC’s holdings, making the stock its largest position. Acuta Capital Partners LLC owned approximately 0.11% of Vaxcyte worth $15,472,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PCVX. China Universal Asset Management Co. Ltd. lifted its stake in shares of Vaxcyte by 68.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after acquiring an additional 8,685 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after purchasing an additional 32,149 shares in the last quarter. Natixis Advisors LLC lifted its position in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares during the period. Tri Locum Partners LP purchased a new stake in Vaxcyte in the 2nd quarter valued at approximately $8,559,000. Finally, Hsbc Holdings PLC acquired a new position in Vaxcyte during the 2nd quarter worth approximately $1,053,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 28.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jim Wassil sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total value of $1,119,300.00. Following the completion of the transaction, the chief operating officer now owns 207,503 shares of the company’s stock, valued at approximately $23,225,810.79. This represents a 4.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,464 shares of company stock valued at $11,455,576 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Trading Up 2.8 %

PCVX stock opened at $93.98 on Thursday. The company has a market cap of $11.71 billion, a PE ratio of -20.43 and a beta of 1.01. The stock has a 50-day moving average price of $106.48 and a two-hundred day moving average price of $89.97. Vaxcyte, Inc. has a 12-month low of $48.81 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the business earned ($0.91) earnings per share. Equities analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PCVX. Bank of America raised their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Jefferies Financial Group raised their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.